The novel technology by Prof. Nissim Benvenisty utilizes stem cells as models for genetic disorders and enables large scale screening of small molecule drugs
Where science meets art meets a branding experience: a new coffee experience thanks to Prof. Shlomo Magdassi's printing invention.
The BioDesign: Medical Innovation program, a joint effort of the Hebrew University of Jerusalem and the Hadassah Medical Center, allowed Sharon to recruit top engineering and business students to help her develop an alternative technology.
Prof. Yaakov Nahmias and Prof. Nissim benvenisty of the Hebrew University's Faculy of Science persent breakthrough research that may be the future alternative to animal trials.
The Global Innovation Awards were established by leading Chinese management consulting firm Shengjing Group and are taking place in China, the U.S., Europe, Latin America and Israel. The Israel segment of the competition was led by...
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has entered into a definitive license and research agreement with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's...
Qlight was founded in 2009 on the basis of technology developed in Prof. Uri Banin's laboratory at the Hebrew University of Jerusalem and commercialized by Yissum Technology Transfer Company of the Hebrew University of Jerusalem. The company was...
Ripples Brings Customizable Latte Art To Your Local Coffee Shop using edible nanoinks invented by Prof. Shlomo Magdassi of the Hebrew University of Jerusalem.
Jerusalem, Israel, June 18, 2015 – Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that it had signed multiple research and licensing agreements in the area of...
The innovative projects by Fourth Year students now face further development by the teams with the gudance of Yissum, the University's Technology Transfer Co.
NEW YORK, June 10, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) announced today that it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem...
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that research underlying BL-9020, for the treatment of Type...